  Disease-modifying treatments are currently assessed in neurodegenerative
diseases. Huntington's Disease represents a unique opportunity to design
automatic sub-clinical markers, even in premanifest gene carriers. We
investigated phonatory impairments as potential clinical markers and propose
them for both diagnosis and gene carriers follow-up. We used two sets of
features: Phonatory features and Modulation Power Spectrum Features. We found
that phonation is not sufficient for the identification of sub-clinical
disorders of premanifest gene carriers. According to our regression results,
Phonatory features are suitable for the predictions of clinical performance in
Huntington's Disease.
